David A. Siegel Uro Gen Pharma Ltd. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,800 shares of URGN stock, worth $315,464. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,800
Previous 18,300
2.73%
Holding current value
$315,464
Previous $274,000
2.92%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding URGN
# of Institutions
113Shares Held
24MCall Options Held
46.9KPut Options Held
44.3K-
Rtw Investments, LP New York, NY3.26MShares$54.7 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.62MShares$44 Million9.62% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$38.6 Million0.26% of portfolio
-
Black Rock Inc. New York, NY1.72MShares$28.8 Million0.0% of portfolio
-
Cowen And Company, LLC1.63MShares$27.3 Million0.82% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $382M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...